MiMedx outlines 2027 revenue well in excess of $400M with over 20% adjusted EBITDA margin following planned Sanara deal (NASDAQ:MDXG)

MiMedx (MDXG) has provided explicit 2027 guidance projecting revenues exceeding $400M with adjusted EBITDA margins surpassing 20%, representing substantial scale and profitability expansion. This forward guidance signals management confidence in operational execution and market demand recovery in the regenerative medicine and wound care segments.

The planned acquisition of Sanara represents a strategic consolidation designed to capture meaningful synergies. The transaction appears calibrated to accelerate growth across surgical and wound-care verticals while driving margin accretion through cost integration and revenue cross-selling—typical catalysts for M&A-driven valuation re-rating in health-care specialties.

Current quarter results ($64M sales with stabilization in wound categories and growth in surgical applications) demonstrate underlying business momentum supporting the 2027 targets. The trajectory from Q2 2026 baselines to $400M+ revenues implies mid-to-high teen compound annual growth, contingent on Sanara integration and market expansion.

Sector implication: Consolidation in specialty health care, particularly in wound-care and regenerative medicine, continues to drive operational leverage and margin expansion. MDXG's guidance and M&A activity reinforce investor appetite for profitable health-care services with recurring revenue models and technical barriers to entry.